| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
1,340,000,000 |
| Market
Cap: |
106.85(B) |
| Last
Volume: |
23,255,346 |
Avg
Vol: |
0 |
| 52
Week Range: |
$69.43 - $91.38 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 125 |
| Guru Rank Value : 7.5 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Medtronic is a medical technology, services and solutions company. Co.'s four operating and reportable segments are as follows: Cardiovascular Portfolio, which is made up of the cardiac rhythm and heart failure, structural heart and aortic, and coronary and peripheral vascular divisions; Medical Surgical Portfolio, which is made up of the surgical innovations and respiratory, gastrointestinal, and renal divisions; Neuroscience Portfolio is made up of the cranial and spinal technologies, specialty therapies, and neuromodulation divisions; and Diabetes Operating Unit, which develops, manufactures, and markets products and services for the management of Type 1 and Type 2 diabetes.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
31,549 |
36,546 |
56,412 |
75,447 |
| Total Sell Value |
$2,684,057 |
$3,094,660 |
$4,783,517 |
$6,318,268 |
| Total People Sold |
2 |
3 |
5 |
5 |
| Total Sell Transactions |
2 |
3 |
8 |
10 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lerman Bradley E |
SVP General Counsel & Corp Sec |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,019 |
48,763 |
|
- |
|
| Lerman Bradley E |
SVP General Counsel & Corp Sec |
• • – |
2021-08-02 |
4 |
D |
$131.31 |
$715,640 |
D/D |
(5,450) |
42,744 |
|
- |
|
| Lerman Bradley E |
SVP General Counsel & Corp Sec |
• • – |
2021-08-02 |
4 |
AS |
$131.52 |
$526,080 |
D/D |
(4,000) |
48,194 |
|
-14% |
|
| Kuntz Richard |
SVP & Chief Medical & Science |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,029 |
74,915 |
|
- |
|
| Kuntz Richard |
SVP & Chief Medical & Science |
• • – |
2021-08-02 |
4 |
D |
$131.31 |
$644,076 |
D/D |
(4,905) |
69,886 |
|
- |
|
| Kirk Jennifer M |
Chief Accounting Officer |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,143 |
8,387 |
|
- |
|
| Salmon Sean |
EVP & Pres Diabetes/Cardiovasc |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,486 |
33,329 |
|
- |
|
| Salmon Sean |
EVP & Pres Diabetes/Cardiovasc |
• • – |
2021-08-02 |
4 |
D |
$131.31 |
$298,336 |
D/D |
(2,272) |
27,843 |
|
- |
|
| Surface Carol A |
SVP, Chief HR Officer |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,657 |
34,327 |
|
- |
|
| Surface Carol A |
SVP, Chief HR Officer |
• • – |
2021-08-02 |
4 |
D |
$131.31 |
$524,846 |
D/D |
(3,997) |
30,670 |
|
- |
|
| Liddicoat John R |
EVP & President of Americas |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,353 |
42,847 |
|
- |
|
| Liddicoat John R |
EVP & President of Americas |
• • – |
2021-08-02 |
4 |
D |
$131.31 |
$427,808 |
D/D |
(3,258) |
39,494 |
|
- |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,333 |
25,395 |
|
- |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-08-02 |
4 |
D |
$131.31 |
$194,601 |
D/D |
(1,482) |
20,062 |
|
- |
|
| Martha Geoffrey |
CEO |
• • – |
2021-06-28 |
4 |
AS |
$125.29 |
$1,440,835 |
D/D |
(11,500) |
81,948 |
|
-2% |
|
| Martha Geoffrey |
CEO |
• • – |
2021-06-28 |
4 |
OE |
$55.32 |
$636,180 |
D/D |
11,500 |
93,448 |
|
- |
|
| Parkhill Karen L |
EVP & Chief Financial Officer |
• • – |
2021-06-22 |
4 |
GA |
$0.00 |
$0 |
I/I |
714 |
843 |
|
- |
|
| Parkhill Karen L |
EVP & Chief Financial Officer |
• • – |
2021-06-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
714 |
85,509 |
|
- |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-06-21 |
4 |
AS |
$123.50 |
$14,203 |
D/D |
(115) |
21,602 |
|
-2% |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-06-18 |
4 |
D |
$123.23 |
$115,590 |
D/D |
(938) |
21,717 |
|
- |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-06-18 |
4 |
OE |
$74.84 |
$87,413 |
D/D |
1,168 |
22,655 |
|
- |
|
| Parkhill Karen L |
EVP & Chief Financial Officer |
• • – |
2021-06-15 |
4 |
AS |
$124.47 |
$75,304 |
D/D |
(605) |
86,223 |
|
-3% |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-06-01 |
4 |
AS |
$128.07 |
$316,717 |
D/D |
(2,473) |
21,487 |
|
2% |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-05-28 |
4 |
D |
$126.59 |
$931,069 |
D/D |
(7,355) |
23,960 |
|
- |
|
| Wall Brett A. |
EVP & Pres Neuroscience |
• • – |
2021-05-28 |
4 |
OE |
$47.00 |
$578,100 |
D/D |
12,300 |
31,315 |
|
- |
|
681 Records found
|
|
Page 7 of 28 |
|
|
0.49 (0.62%) 
